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Abstract. 
 
We have generated F9 murine embryonal 
carcinoma cells in which either the retinoid X receptor 
 
(RXR)
 
a
 
 and retinoic acid receptor (RAR)
 
a
 
 genes or 
the RXR
 
a
 
 and RAR
 
g
 
 genes are knocked out, and com-
pared their phenotypes with those of wild-type (WT), 
 
RXR
 
a
 
2
 
/
 
2
 
, RAR
 
a
 
2
 
/
 
2
 
, and RAR
 
g
 
2
 
/
 
2
 
 cells. RXR
 
a
 
2
 
/
 
2
 
/
RAR
 
a
 
2
 
/
 
2
 
 cells were resistant to retinoic acid treatment 
for the induction of primitive and parietal endodermal 
differentiation, as well as for antiproliferative and apop-
totic responses, whereas they could differentiate into 
visceral endodermlike cells, as previously observed for 
RXR
 
a
 
2
 
/
 
2
 
 cells. In contrast, RXR
 
a
 
2
 
/
 
2
 
/RAR
 
g
 
2
 
/
 
2
 
 cells 
were defective for all three types of differentiation, as 
well as antiproliferative and apoptotic responses, indi-
cating that RXR
 
a
 
 and RAR
 
g
 
 represent an essential re-
ceptor pair for these responses. Taken together with re-
sults obtained by treatment of WT and mutant F9 cells 
with RAR isotype– and panRXR-selective retinoids, 
our observations support the conclusion that RXR/
RAR heterodimers are the functional units mediating 
the retinoid signal in vivo. Our results also indicate that 
the various heterodimers can exert both specific and re-
dundant functions in differentiation, proliferation, and 
apoptosis. We also show that the functional redundancy 
exhibited between RXR isotypes and between RAR 
isotypes in cellular processes can be artifactually gener-
ated by gene knockouts. The present approach for mul-
tiple gene targeting should allow inactivation of any set 
of genes in a given cell.
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1. 
 
Abbreviations used in this paper
 
: AFP, 
 
a
 
-fetoprotein; E
 
2
 
, estradiol; EC,
embryonal carcinoma; EMSA, electrophoretic mobility shift assays; HR,
homologous recombination; PGK, phosphoglycerate kinase; RAR, retin-
oic acid receptor; RXR, retinoid X receptor; RARE, retinoic acid re-
sponse element; RT, reverse transcription; tRA, all-trans retinoic acid;
VE, visceral endoderm; WT, wild-type.
 
R
 
etinoids 
 
exert their pleiotropic effects on verte-
brate development, cellular differentiation, prolif-
eration, and homeostasis through two classes of
ligand-dependent transactivators: the retinoic acid recep-
tors (RARs)
 
1
 
, and the retinoid X receptors (RXRs) (for
reviews see De Luca, 1991; Blomhoff, 1994; Chambon,
1994, 1996; Kastner et al., 1995; Mangelsdorf and Evans,
1995). RARs are activated by all-
 
trans
 
 retinoic acid (tRA)
and by 9-
 
cis
 
 retinoic acid (9C-RA), whereas RXRs are ac-
tivated by 9C-RA only. The various RAR (RAR
 
a
 
, 
 
b
 
, and
 
g
 
) and RXR (RXR
 
a
 
, 
 
b
 
, and 
 
g
 
) isotypes are encoded by
different genes, and their isoforms, which differ in their
NH
 
2
 
-terminal regions, are generated by differential pro-
moter usage and alternative splicing. The multiple RAR
and RXR isotypes and isoforms are conserved in verte-
brate evolution, and display distinct spatiotemporal ex-
pression patterns in developing embryos and adult tissues,
suggesting that each receptor performs some unique func-
tions (for reviews see Leid et al., 1992
 
a
 
; Chambon, 1994;
Kastner et al., 1994). RXR/RAR heterodimers bind much
more efficiently to retinoic acid response elements (RAREs)
than their respective homodimers in vitro (for reviews see
Leid et al., 1992
 
a
 
; Chambon, 1994, 1996; Giguère, 1994;
Glass, 1994; Kastner et al., 1994; Mangelsdorf et al., 1994;
Gronemeyer and Laudet, 1995; Keaveney and Stunnen-
berg, 1995; Mangelsdorf and Evans, 1995), and several lines
of evidence support the idea that these heterodimers rep-
resent the functional units transducing the retinoid signal in
vivo (Kastner et al., 1995; Chambon, 1996).
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The F9 murine embryonal carcinoma (EC) cell line ex-
presses all types of RARs and RXRs (Zelent et al., 1989;
Martin et al., 1990; Wan et al., 1994), and upon retinoic
acid treatment, it differentiates into cells resembling three
distinct extraembryonic endoderm (primitive, parietal,
and visceral), depending on the culture conditions (for re-
views see Strickland, 1981; Hogan et al., 1983; Gudas et al.,
1994). Retinoid-induced differentiation is accompanied by
an apoptotic response and a dramatic decrease in the rate
of proliferation (Sleigh, 1992; Atencia et al., 1994; Clifford
et al., 1996). Thus, F9 cells provide an attractive system for
the analysis of retinoid signaling in vivo.
To further investigate the roles of RXRs and RARs in
differentiation, proliferation, and apoptosis, we have now
generated F9 cells lacking either RXR
 
a
 
 and RAR
 
a
 
, or
RXR
 
a
 
 and RAR
 
g
 
, and then compared their phenotypes
with those of wild-type (WT), RXR
 
a
 
2
 
/
 
2
 
 (Clifford et al.,
1996), RAR
 
a
 
2
 
/
 
2
 
 (Boylan et al., 1995), and RAR
 
g
 
2
 
/
 
2
 
(Boylan et al., 1993; Taneja et al., 1995) F9 cells. Multiple
gene targeting in a given cell has been achieved by using a
Cre/
 
loxP
 
 system (Sauer and Henderson, 1990; Metzger et
al., 1995), which allows removal of the antibiotic resistance
gene from a targeted locus, and therefore subsequent mu-
tagenesis of the second allele of a given gene with the
same targeting construct, as well as the targeting of addi-
tional genes. We demonstrate that tRA-treated RXR
 
a
 
2
 
/
 
2
 
/
RAR
 
a
 
2
 
/
 
2
 
 cells differentiate poorly into primitive and pa-
rietal endodermlike cells and are impaired in both antipro-
liferative and apoptotic responses, whereas they fully dif-
ferentiate into visceral endoderm (VE)-like cells, as previously
observed for RXR
 
a
 
2
 
/
 
2
 
 cells (Clifford et al., 1996). In con-
trast, RXR
 
a
 
2
 
/
 
2
 
/RAR
 
g
 
2
 
/
 
2
 
 cells are defective for all three
types of endodermal differentiation, as well as for the anti-
proliferative and apoptotic responses, indicating that the
absence of both RXR
 
a
 
 and RAR
 
g
 
 cannot be functionally
compensated by the other retinoid receptors in these cells.
Taken together with results obtained by treatment of
WT and mutant F9 cells with panRXR- and RAR isotype–
selective retinoids, our findings support the conclusion
that RXR/RAR heterodimers are the functional units me-
diating the retinoid signal in vivo. Furthermore our results
indicate that RXR/RAR heterodimers can exert both spe-
cific and redundant functions in differentiation, proliferation,
and apoptosis. We also show that functional redundancy
between RXR isotypes and between RAR isotypes can be
artifactually generated by gene knockouts.
 
Materials and Methods
 
Cell Culture
 
F9 cells were cultured and induced to differentiate into primitive, parietal,
and visceral endodermlike cells as previously described (Boylan et al.,
1993; Clifford et al., 1996). The retinoids (tRA, Am80, BMS753, BMS453,
BMS961, and BMS649) were dissolved in ethanol.
 
Targeting of the RAR
 
a
 
 or RAR
 
g
 
 Genes in RXR
 
a
 
-null 
F9 Cells.
 
The RAR
 
a
 
 targeting vector, pRAR
 
a
 
(LNL)
 
, was previously described
(Metzger et al., 1995). The RAR
 
g
 
 targeting vector, pRAR
 
g
 
(LPL)
 
, was de-
rived from pD
 
g
 
6.5A (a gift from D. Lohnes, IGBMC, CNRS/INSERM/
ULP, Illkirch, France), which contains a 6-kb genomic fragment including
exons 5 and 8. A unique SmaI site, followed by stop codons in all three
reading frames, was introduced into pD
 
g
 
6.5A at the KpnI site located in
exon 8 of RAR
 
g
 
 by inserting the oligonucleotides 5
 
9
 
-CCCCGGGTAGG-
TAGATAGCGTAC-3
 
9
 
 and 5
 
9
 
-GCTATCTACCTACCCGGGGGTAC-3
 
9
 
,
yielding the pRAR
 
g
 
T4 construct. An XhoI-BamHI fragment contain-
ing  the phosphoglycerate kinase (PGK) promoter-driven, puromycin-
resistance (puro) gene, flanked by 
 
loxP
 
 sites, was isolated from pHRLpuro1,
and blunt ended with T4 DNA polymerase, followed by ligation into the
SmaI site of pRAR
 
g
 
T4. pHRLpuro1 was constructed from VS-1, a plas-
mid containing a 
 
loxP
 
 site-flanked PGKpuroA
 
1
 
 cassette, by mutating the
SalI site. The PGKpuroA
 
1
 
 cassette was obtained by ligating the PGK pro-
Figure 1. Disruption of both alleles of the RARa gene by HR in
a RXRa2(L)/2(L) cell line. (A) Schematic diagram of the pRARa(LNL)
targeting construct, the WT RARa locus, and the recombined lo-
cus after integration (HR[I]) and after Cre-mediated excision
(HR[E]). Dark boxes indicate exons. The exons 4–8 encoding the
NH2-terminal part of minor isoforms (RARa3-7) (Leroy et al.,
1991) are not represented. Restriction enzyme sites and the loca-
tion of probes are indicated. The neo and a1 probes have been
previously described (Metzger et al., 1995). The numbers in the
lower part of diagram are in kb. K, KpnI; L, loxP recombination
site; S, SalI; ST, two translation stop codons; Xb, XbaI; Xh, XhoI.
(B) Southern blot analysis indicating the targeting of the RARa
gene in a RXRa2(L)/2(L) cell line. The genotypes of different cell
lines (e.g., 9) and their subclones (9a, etc.) are indicated at the top
of each lane, and correspond to all three panels. (C) Western blot
analysis indicating the absence of RARa protein in RXRa2(L)/2(L)/
RARa2(L)/2(LNL) cell lines. Lanes 1 and 2 contain 2 mg of whole
cell extracts from COS cells transfected with either the pSG5
(Green et al., 1988) or mRARaø expression construct (Zelent et
al., 1989), and lanes 3–6 contain 60 mg of whole cell extracts from
WT and mutant F9 cells, as indicated. RARa protein was de-
tected using the rabbit polyclonal antibody RPa(F), followed by
chemiluminescence detection. Mol wt is shown in kD.Chiba et al. Function of RXR/RAR Heterodimers in F9 Cells 737
Figure 2. Disruption of both alleles of the RARg gene by HR in
a RXRa2(L)/2(L) cell line. (A) Schematic diagram of the pRARg(LPL)
targeting construct, the WT RARg locus, and the recombined lo-
cus after integration (HR[I]) and after Cre-mediated excision
(HR[E]). Dark boxes indicate exons. The exons 6 and 7 encoding
the NH2-terminal part of minor isoforms (RARg4 and 6; Kastner
et al., 1990) are not represented. Restriction enzyme sites and the
location of probes are indicated. The puro probe corresponds to a
0.7-kb EcoRI-XbaI fragment derived from pHRLpuro1. The r1
probe corresponds to a 1.5-kb BamHI–EcoRI fragment derived
from the RARg genomic clone lG1mRARg (Lohnes et al.,
1993). The r2 probe corresponds to a 1.6-kb EcoRI–PstI fragment
derived from pRARg(LPL). The numbers in the lower part of the
diagram are in kb. B, BamHI; Bg, BglII; E, EcoRI; H, HindIII; L,
loxP recombination site; S, SalI; ST, three translation stop codons
inserted in all reading frames. Asterisk indicates that these sites
are not present in the WT gene, and dashed line represents vector
sequence. (B) Southern blot analysis indicating the disruption of
the RARg gene in a RXRa2(L)/2(L) cell line. The genotypes of
different cell lines (e.g., 25) and their subclones (25a, etc.) are in-
dicated at the top of each lane and correspond to all four panels.
(C) EMSA indicating the absence of RARg protein in RXRa2(L)/2(L)/
RARg2(L)/2(LNL) cells. A radiolabeled oligonucleotide correspond-
ing to the Hoxa-1/RARb RARE was incubated with 20 mg of
whole cell extracts from WT cells (lanes 1 and 4), RXRa2(L)/2(L)/
RARg2(L)/2(LNL) cells (lanes 2 and 5) and RARg2/2 cells (lanes 3
and 6), or with 2 mg of whole cell extracts from COS cells trans-
fected with either the pSG5 (lanes 7 and 9; Green et al., 1988) or
mRARgø expression construct (lanes 8 and 10; Zelent et al.,
1989), together with 0.5 mg of whole cell extracts from COS cells
transfected with mRXRaø expression construct (Leid et al.,
1992b). The arrows indicate the shifted complex formed in the
presence of mouse monoclonal antibodies Ab2g(F) and Ab10g
(A2).
moter (a 500-bp EcoRI-PstI fragment isolated from pKJ-1 [Adra et al.,
1987]) to the coding sequence of the puro gene (a 600-bp HindIII-ClaI
fragment isolated from pLXPB [Imler et al., 1996]), and by inserting the
SV-40 polyadenylation signal (a 160-bp BglII-XbaI fragment isolated from
pSG5 [Green et al., 1988]) using synthetic oligonucleotides. This cloning
resulted in the loss of the PstI, HindIII, and ClaI restriction sites, and the
introduction of HindIII and EcoRI sites at 59 and 39 ends of the PGK pro-
moter, respectively. KpnI, ApaI, XhoI, and BglII restriction sites, and
BamHI and SacI sites are located at 59 and 39 ends of the loxP-flanked
cassette, respectively.
Electroporation, selection of neomycin-resistant clones, Cre-mediated
excision of the resistance genes, and Southern blot analysis were per-
formed as previously described (Metzger et al., 1995; Clifford et al., 1996).
Puromycin selection (500 ng/ml) was carried out for 10 d.
Western Blotting and Electrophoretic Mobility Shift 
Assays (EMSA)
Isolation of whole cell extracts from F9 cells and transfected COS-1 cells,
Western blot analysis, and electrophoretic mobility shift assays were per-
formed as previously described (Rochette-Egly et al., 1991; Gaub et al.,
1992; Boylan et al., 1993).
Reverse Transcription (RT)-PCR
RNA preparation, RT-PCR, and Southern blotting were performed as
previously described (Bouillet et al., 1995; Roy et al., 1995). The PCR
primers and end-labeled oligonucleotide probes for collagen IVa1, lami-
nin B1, a-fetoprotein (AFP), and 36B4, were described previously (Clif-
ford et al., 1996). Transcript levels were quantified using a BAS 2000 bio-
imaging analyzer (Fuji Ltd., Tokyo, Japan), and were normalized to the
corresponding 36B4 signals.
Analysis of Cellular Growth
Cells were plated in triplicate 3-cm culture wells (5 3 102 cells per well),
and cell counting experiments were performed as previously described
(Clifford et al., 1996). [3H]Thymidine incorporation assays were per-
formed essentially as described (Clifford et al., 1996), with the following
modifications. Cells were cultured for 4 d in six replicate 3-cm wells, in the
presence or absence of 1 mM tRA, and three of the six wells were treated
with 8 mCi/well [3H]methylthymidine (20.0 Ci/mmol; Dupont-NEN, Bos-
ton, MA) for 2 h before harvesting. The cell cycle profile of WT and mu-
tant cells was determined as previously described (Clifford et al., 1996).
Analysis of Apoptosis
Apoptosis was analyzed by both Hoechst staining of nuclei and FACS®
analysis, as previously described (Clifford et al., 1996).
Results
Targeted Disruption of the RARa or RARg Genes in 
RXRa Null F9 Cells
The RXRa-null F9 cell line, C2RXRa2(L)/2(L), which con-
stitutively expresses a ligand-dependent chimeric Cre-
recombinase (Cre-ER; Metzger et al., 1995), was elec-
troporated with the targeting constructs pRARa(LNL) (Fig.
1 A) or pRARg(LPL) (Fig. 2 A) to generate F9 cells dis-
rupted in either the RXRa and RARa genes or the RXRa
and RARg genes. These targeting constructs contain
translation stop codons and loxP site–flanked neomycin-
or puromycin-resistance genes in exon 9 of the RARaThe Journal of Cell Biology, Volume 139, 1997 738
gene or exon 8 of the RARg gene, respectively (Materials
and Methods; Figs. 1 A and 2 A). Since these exons encode
the B region, which is common to all isoforms of a given
RAR isotype (Kastner et al., 1990; Leroy et al., 1991;
Chambon, 1994), the expression of RARa and RARg pro-
teins is suppressed by these mutations. Homologous re-
combination (HR) and Cre-mediated excision of the resis-
tance genes were verified by Southern blotting (Figs. 1 B
and 2 B).
Southern blot analysis using a 39 probe (a1) located outside
of the pRARa(LNL) targeting construct (Fig. 1 A), indicated
that, after electroporation, 5 out of 96 C2RXRa2(L)/2(L)
neomycin-resistant clones had one targeted RARa allele
(Fig. 1, A, HR[I]; and B, compare lanes 3 and 4 with lanes 1
and 2; data not shown). One RXRa2(L)/2(L)/RARa1/2(LNL)
cell line (clone nine) was treated with estradiol (E2) to ex-
cise the loxP-flanked cassette (2[LNL] and 2[L]) desig-
nate the targeted allele before and after Cre-mediated ex-
cision, respectively). Southern blot analysis using a1 and
“neo” probes revealed that excision of the resistance gene
occurred in two out of six subclones treated with E2 (Fig.
1, A, HR[E]; and B, compare lane 5 with lanes 3 and 4; see
also Metzger et al., 1995). The second allele of the RARa
gene was targeted in the RXRa2(L)/2(L)/RARa1/2(L) cell
line (Fig. 1 B, clone 9a) using the same targeting construct
and strategy. 2 of 96 neomycin-resistant clones were posi-
tive for the desired recombination event, resulting in
RXRa2(L)/2(L)/RARa2(L)/2(LNL) cell lines (Fig. 1 B, clones
9a-10 and 9a-26; compare lanes 6 and 7 with lanes 1–5). No
wild-type RARa transcripts were detected in RXRa2(L)/2(L)/
RARa2(L)/2(LNL) cells by semi-quantitative RT-PCRs (data
not shown). Similarly, no RARa protein could be detected
in RXRa2(L)/2(L)/RARa2(L)/2(LNL) cells (called hereafter
RXRa2/2/RARa2/2) by Western blotting using the poly-
clonal antibody RPa(F) (Gaub et al., 1992), directed
against the F region of the RARa protein (Fig. 1 C, com-
pare lanes 3 and 4 with lanes 2, 5, and 6).
To establish F9 cells in which both RXRa and RARg
genes are inactivated, C2RXRa2(L)/2(L) cells were elec-
troporated with the pRARg(LPL) targeting construct (Fig. 2
A). Southern blot analysis using the r1 probe, located 59 to
the pRARg(LPL) sequence (Fig. 2 A), revealed that 3 out of
96 puromycin-resistant clones had one targeted RARg al-
lele (Fig. 2, A, HR[I]; and B, compare lanes 3 and 4 with
lanes 1 and 2; and data not shown). One RXRa2(L)/2(L)/
RARg1/2(LPL) cell line (clone 25) was transiently transfected
with a Cre recombinase expression construct (pPGK-Cre)
(Clifford et al., 1996), since for unknown reasons the loxP-
flanked, puromycin-resistance gene was not excised by
treatment of the cells with E2 (data not shown; 2[LPL]
and 2[L] designate the targeted allele before and after
Cre-mediated excision, respectively). The pattern ob-
tained by Southern blot analysis, using r1, r2, and puro
probes, clearly indicated that 2 out of 96 subclones had lost
the puromycin-resistance cassette (Fig. 2, A, HR[E]; and
B, compare lane 5 with lane 4; and data not shown). The
second allele of the RARg gene was inactivated in one
RXRa2(L)/2(L)/RARg1/2(L) cell line (Fig. 2 B, clone 25a)
Figure 3. RXRa2/2/RARg2/2
F9 cells do not differentiate
into primitive and parietal en-
dodermlike cells. (A) WT (a–
c), RXRa2/2 (d–f), RXRa2/2/
RARa2/2 (g–i) and RXRa2/2/
RARg2/2 ( j–l) cells were
treated with control vehicle
(a, d, g, and j), 1 mM tRA
alone (b, e, h, and k) or 1 mM
tRA and 250 mM bt2cAMP
(c, f, i, and l) for 4 d. Cells
were photographed under a
phase–contrast microscope
at  3125 magnification. (B)
Total RNA from WT and
mutant cells, treated with
control vehicle or 1 mM tRA
for 48 h, was analyzed by RT-
PCR analysis for collagen
type IVa1, laminin B1, and
36B4. (C) RT-PCR analysis
was performed as in B, for
three separate experiments.
The levels of RNA tran-
scripts were expressed rela-
tive to the amount present in
tRA-treated WT cells, which
was taken as 100. The white
and black bars correspond to
transcript levels expressed in
vehicle- and tRA-treated cells,
respectively. Bar, 100 mm.Chiba et al. Function of RXR/RAR Heterodimers in F9 Cells 739
using the same targeting construct and strategy, yielding a
RXRa2(L)/2(L)/RARg2(L)/2(LPL) cell line (Fig. 2 B, clone
25a-3, compare lane 6 with lanes 1–5). No wild-type RARg
RNA was detected in RXRa2(L)/2(L)/RARg2(L)/2(LPL) cells
(data not shown). The absence of RARg protein was veri-
fied by EMSA using the monoclonal antibodies Ab2g(F)
and Ab10g(A2) (Rochette-Egly et al., 1991), directed against
the F and A2 regions of the RARg protein, respectively.
No antibody-shifted complex was observed in RXRa2(L)/2(L)/
RARg2(L)/2(LPL) cells (called hereafter RXRa2/2/RARg2/2)
(Fig. 2 C, compare lane 5 with lanes 4, 6, and 10). Note
that the RXRa loci, which contain loxP sites, were not re-
arranged during excision of the resistance genes at the
RARa or RARg loci (data not shown). Note also that the
knockout of a given receptor(s) did not result in major
variations of those remaining (Chiba et al., 1997).
Function of RXRs and RARs in the Retinoid-induced 
Differentiation of F9 Cells into Primitive and Parietal 
Endodermlike Cells
WT F9 cells differentiate into primitive and parietal endo-
dermlike cells, when grown in monolayer culture in the
presence of tRA alone and tRA in combination with dibu-
tyryl cAMP (bt2cAMP), respectively (Strickland, 1981;
Hogan et al., 1983). Previous studies have shown that
these two types of differentiation are severely impaired in
RARg2/2 and RXRa2/2 cells (Boylan et al., 1993; Clifford
et al., 1996). The differentiation patterns of RXRa2/2/
RARa2/2 and RXRa2/2/RARg2/2 cells were compared
with those of WT and single knockout cell lines. After 4 d
of treatment, ,10% of RXRa2/2/RARa2/2 cells became
flatter and irregular in shape, or rounded with long cell
processes, which are the morphological characteristics of
primitive or parietal endodermal differentiation of WT F9
cells, respectively. The same results were obtained with
9a-10 and 9a-26 RXRa2/2/RARa2/2 cell lines (Fig. 3 A,
compare g–i with a–f, and data not shown). No morpho-
logical differentiation at all was observed in RXRa2/2/
RARg2/2 cells after 4 d of treatment, and ,0.1% of the
cells exhibited a differentiated morphology after 6 d of
treatment (Fig. 3 A, j–l, and data not shown). This undif-
ferentiated phenotype persisted after 10 d of treatment.
The extent of differentiation of WT and mutant F9 cells
was further investigated biochemically by determining the
mRNA levels of collagen type IVa1 and laminin B1, two
markers of endodermal differentiation (Fig. 3, B and C).
After 48 h of 1 mM tRA treatment, the induction of col-
lagen type IVa1 and laminin B1 was reduced in RARg2/2
cells (10-fold and 6-fold lower levels, respectively) and in
RXRa2/2 cells (3-fold and 6-fold lower levels, respec-
tively) when compared to WT cells, whereas these induc-
tions were not altered in RARa2/2 cells (Boylan et al.,
1993, 1995; Clifford et al., 1996; Taneja et al., 1996). The
induction of both transcripts was also impaired in RXRa2/2/
RARa2/2 cells (fivefold and sevenfold lower levels, re-
spectively), whereas it was fully abrogated in RXRa2/2/
RARg2/2 cells. Thus, RA-induced primitive and parietal
endodermal differentiation of WT F9 cells appears to be
mainly mediated by the RXRa/RARg pair, whereas it
cannot be mediated by combinations of RXR(b1g) with
either RARa or RARb (see Table IV).
Function of RXRs and RARs in the Retinoid-induced 
Differentiation of F9 Cells into VE-like Cells
When F9 cells are grown in suspension as aggregates, low
levels of tRA induce a VE phenotype in the outermost
layer of cells, which display an irregular surface (Strick-
land, 1981; Hogan et al., 1983; see also Fig. 4 A, WT, a and
b, brackets). We have previously shown that, in contrast to
primitive and parietal endodermal differentiation, VE dif-
ferentiation can be induced by tRA in RXRa2/2 F9 cells
(Clifford et al., 1996). Similarly, after 10 d of treatment,
Figure 4. RXRa2/2/RARg2/2
F9 cells are defective for
tRA-induced differentiation
into VE-like cells. (A) WT (a
and b), RXRa2/2 (c and d),
RXRa2/2/RARa2/2 ( e  and
f), RARg2/2 (g and h), and
RXRa2/2/RARg2/2 (i and j)
cells were grown in suspen-
sion in the absence (a, c, e, g,
and i) or presence (b, d, f, h,
and j) of 50 nM tRA for 10 d.
The aggregates were photo-
graphed under a phase–con-
trast microscope at 3125 magnification. The arrows and brackets
indicate VE morphology. (B) Total RNA from WT and mutant
aggregates, treated with control vehicle or 50 nM tRA for 10 d,
was subjected to RT-PCR analysis for collagen IVa1, laminin B1,
AFP, and 36B4. Similar results were obtained for three indepen-
dent experiments. Bar, 100 mm.The Journal of Cell Biology, Volume 139, 1997 740
.80% of the outer layer of RARa2/2 and RXRa2/2/
RARa2/2 cell aggregates differentiated into VE-like cells,
which were indistinguishable from those of WT and
RXRa2/2 cells (Fig. 4 A, compare f with panels b and d;
and Table I). In contrast, ,10% of the outer layer of
RARg2/2 cells exhibited VE conversion after 10 d of
treatment, whereas full VE differentiation was eventually
achieved after 14 d of treatment (Fig. 4 A, compare h with
g and b; and Table I). In RXRa2/2/RARg2/2 cells, the sur-
face of the aggregates was as smooth after 10 d of treat-
ment as in untreated controls (Fig. 4 A, compare j with a
and i), and ,10% of the aggregates displayed only a spotty
VE conversion after 12 or 18 d of treatment (Table I). To
exclude the possibility that this very poor differentiation
of the RXRa2/2/RARg2/2 cells could be due to some
clonal variation, rather than the presence of the RXRa-
null mutation in the RARg-null background, we expressed
the RXRa cDNA in RXRa2/2/RARg2/2 cells. As ex-
pected, cells expressing the RXRa cDNA exhibited a phe-
notype identical to that of RARg2/2 cells, i.e., the RA-
induced VE differentiation was restored at late time (14 d)
of RA treatment (data not shown).
We also analyzed the mRNA levels of collagen type
IVa1, laminin B1 and AFP in WT and mutant F9 cells
(Fig. 4 B). After 10 d of aggregate culture in the presence
of 50 nM tRA, the three markers were similarly induced in
WT, RXRa2/2, RARa2/2, and RXRa2/2/RARa2/2cells.
In RARg2/2 cells, the induction of laminin B1 was similar
to that of WT cells, whereas the induction of collagen IVa1
was slightly reduced (twofold lower than in WT cells). In
contrast, the induction of AFP, a specific marker of VE
differentiation, was hardly detectable in RARg2/2 cells after
10 d of RA treatment (Fig. 4 B). There was no induction of
either collagen IVa1, laminin B1 or AFP in RXRa2/2/
RARg2/2 cells, in agreement with their lack of morpho-
logical differentiation into VE. Thus, RXRa and RARg
play an essential role in VE differentiation of WT F9 cells.
To further investigate the functions of RARs and RXRs
in VE differentiation, WT and mutant F9 cells were treated
for 10–18 d with tRA or synthetic retinoid agonist selective
for RARa (BMS188,753 [BMS753]; Taneja et al., 1996),
RARb (BMS189,453 [BMS453]; Chen et al., 1995), RARg
(BMS188,961 [BMS961]; Taneja et al., 1996) and all three
RXRs (panRXR, BMS188,649 [BMS649]; also known as
SR11237; Lehmann et al., 1992; see Roy et al., 1995) (Ta-
ble I). In WT cells, VE differentiation was triggered by 100
nM of the RARg agonist as effectively as by 50 nM tRA,
and it was synergistically induced by a combination of 10
nM RARg and 1 mM panRXR agonists (Table I). In con-
trast, VE differentiation of RARa2/2 cells was triggered
by 10 nM RARg agonist as efficiently as by 50 nM tRA,
and it was even synergistically induced by 1 nM of the
RARg agonist in combination with 1 mM panRXR ago-
nist, indicating that RARa partially hinders the RARg
function in WT cells. The RARg agonist alone, or to-
gether with the panRXR agonist, was more efficient in
RXRa2/2 and RXRa2/2/RARa2/2 cells than in WT cells, but
weaker than in RARa2/2 cells, demonstrating that RXRa
prevents an efficient synergism between RXR(b1g) and
RARg (Table I; see Table IV). As expected, no VE differ-
entiation was observed in RARg2/2 and RXRa2/2/
RARg2/2 cells treated with the RARg/panRXR agonist
combination.
The RARa agonist, BMS753, on its own did not trigger
VE differentiation of WT and RXRa2/2 cells, whereas the
combination of 100 nM RARa and 1 mM panRXR ago-
nists was much less efficient than the RARg/panRXR ago-
nist combination. As expected, no VE differentiation was
Table I. Effect of Various Retinoids on Morphological Differentiation of WT and Mutant F9 Cells into Visceral Endoderm
(VE)-like Cells
Treatment
WT and mutant F9 cells
WT RXRa2/2 RARa2/2
RXRa2/2
RARa2/2 RARg2/2
RXRa2/2
RARg2/2
Ethanol (2)( 2 )( 2 )( 2 )( 2 )( 2 )
50 nM tRA 111 111 111 111 6(111*) (2) (2‡)
1 mM panRXR agonist (2)( 2 )( 2 )( 2 )( 2 )( 2 )
10 nM RARa agonist (2)( 2 )N DN D ( 2 )N D
100 nM RARa agonist (2)( 2 )( 2 )( 2 ) 6 ( 2 )
500 nM RARb agonist (2)( 2 )( 2 )( 2 ) 6 ( 2 )
1 nM RARg agonist (2)( 2 )( 2 )( 2 )( 2 )N D
10 nM RARg agonist 6 1 111 1 (2)N D
100 nM RARg agonist 111 111 111 111 (2)( 2 )
10 nM RARa 1 1 mM panRXR agonists (2)( 2 )N DN D ( 2 )N D
100 nM RARa 1 1 mM panRXR agonists 66 ( 2 )( 2 ) 11 (2) (6§)
500 nM RARb 1 1 mM panRXR agonists (2)( 2 )( 2 )( 2 ) 11 (2) (6§)
1 nM RARg 1 1 mM panRXR agonists (2)( 2 ) 1 ( 2 )( 2 )N D
10 nM RARg 1 1 mM panRXR agonists 1 111 111 111 (2)( 2 )
100 nM RARg 1 1 mM panRXR agonists 111 111 111 111 (2)( 2 )
WT and mutant F9 cell aggregates were treated for 10 d with the indicated retinoids, and their differentiation was scored according to the proportion of outer layer of cells display-
ing VE morphology. 111, more than 80%; 11, 50–80%; 1, 10–50%; 6, not more than 10%; (2), no visible effect; ND, not determined.
*After 14 d of treatment.
‡After 12 or 18 d of treatment, ,10% of the aggregates exhibited a spotty VE morphology only.
The RARa, RARb, RARg, and panRXR agonists were BMS753, BMS453, BMS961, and BMS649, respectively (see text).
§After 12 or 18 d of treatment.
Note that this visual scoring correlated well with the determination of the relative level of induction of a-fetoprotein RNA using semi-quantitative RT-PCR (Fig. 4 B).Chiba et al. Function of RXR/RAR Heterodimers in F9 Cells 741
seen in RARa2/2 and RXRa2/2/RARa2/2 cells upon
treatment with the RARa/panRXR agonist combination.
In contrast, RARg2/2 cells weakly differentiated into VE-
like cells upon treatment with 100 nM RARa agonist
alone, and this differentiation was markedly enhanced by
addition of 1 mM panRXR agonist. This synergistic stimu-
lation was almost abrogated in RXRa2/2/RARg2/2 cells.
A combination of RARb (BMS453) and panRXR ago-
nists did not trigger VE differentiation in WT, RXRa2/2,
RARa2/2, and RXRa2/2/RARa2/2 cells. Interestingly, this
combination synergistically induced VE differentiation of
RARg2/2 cells, and this effect was almost absent in
RXRa2/2/RARg2/2 cells, as in the case of the RARa/pan-
RXR agonist combination (Table I). Thus, RARg strongly
prevents RARa and RARb to synergize with RXRa, and
mutation of RARg artefactually generates functional re-
dundancy between RARs for VE differentiation of F9
cells (see Table IV).
Figure 5. The antiproliferative response to tRA is impaired in
RXRa2/2 and RXRa2/2/RARa2/2 cells, and is abolished in
RXRa2/2/RARg2/2 F9 cells. (A) The number of cells after 6 d of
culture in the presence (black bars) or absence (white bars) of 1
mM tRA are indicated for WT and mutant cells. The bars repre-
sent the mean 6 SEM for triplicate cultures within the same ex-
periment. (B) Cells were cultured for 4 d with or without 1 mM
tRA, followed by 2 h of [3H]thymidine ([3H]TdR) labeling. The
bars represent the mean 6 SEM for three different experiments,
setting the amount of [3H]TdR incorporation per 1,000 cells
equal to one, for WT control cells. (C) Subconfluent cultures of
WT (a and b), RXRa2/2 (c and d), RXRa2/2/RARa2/2 (e and f),
and RXRa2/2/RARg2/2 (g and h) cells were grown for 5 d in the
presence (b, d, f, and h) or absence (a, c, e, and g) of 1 mM tRA,
and analyzed by FACS®. The X axis indicates the integrated fluo-
rescence intensity and the Y axis the particle number. Approxi-
mately 20,000 particles are represented in each histogram. The
percentage of cells in G11G0, S, and G21M phases are indi-
cated. The arrow highlights the sub-2N size, DNA-containing
particles corresponding to “apoptotic bodies.”
Table II. Effect of Various Retinoids on Proliferation of WT 
and Mutant F9 Cells
Treatment
WT and mutant F9 cells
WT RXRa2/2 RARa2/2
RXRa2/2
RARa2/2 RARg2/2
RXRa2/2
RARg2/2
Ethanol 100 100 100 100 100 100
1 mM tRA 21 42 22 46 28 112
1 mM panRXR
agonist
100 100 100 100 100 100
10 nM RARa
agonist
100 100 100 100 100 124
100 nM RARa
agonist
100 100 100 100 100 143
50 nM RARb
agonist
100 100 ND ND 100 ND
500 nM RARb
agonist
100 100 100 100 100 120
10 nM RARg
agonist
100 100 100 100 100 100
100 nM RARg
agonist
37 51 30 49 100 100
10 nM RARa
1 1 mM
panRXR
agonists
100 100 100 100 100 130
100 nM RARa
1 1 mM
panRXR
agonists
56 100 100 100 40 146
50 nM RARb
1 1 mM
panRXR
agonists
100 100 ND ND 53 ND
500 nM RARb
1 1 mM
panRXR
agonists
100 100 100 100 47 154
10 nM RARg
1 1 mM
panRXR
agonists
60 81 42 77 100 100
100 nM RARg
1 1 mM
panRXR
agonists
31 44 ND ND 100 ND
WT and mutant F9 cells were treated for 6 d in monolayer culture with the indicated
retinoids. In each case, the number of cells was expressed in percent relative to the
number of cells grown in 0.1% ethanol, which was taken as 100%. ND, not deter-
mined. These values correspond to the average of at least three experiments (6 10%).
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Function of RXRs and RARs in the Retinoid-induced 
Antiproliferative Response of F9 Cells and
Retinoid-induced Proliferation of RXRa/RARg Null
F9 Cells
The effect of tRA on proliferation of WT, RXRa2/2,
RXRa2/2/RARa2/2, and RXRa2/2/RARg2/2 F9 cells was
investigated (Fig. 5 A). After 6 d of 1 mM tRA treatment,
the inhibition of growth as determined by cell counting,
was lower for RXRa2/2 than for WT cells (58 and 79% in-
hibition relative to untreated control cells, respectively)
(Clifford et al., 1996). The antiproliferative effect of tRA
was decreased to the same extent for RXRa2/2/RARa2/2
cells (54% inhibition) and RXRa2/2 cells. On the other
hand, tRA did not reduce, but slightly increased the num-
ber of RXRa2/2/RARg2/2 cells. The rate of DNA synthe-
sis was also compared for WT and mutant cell lines by
measuring [3H]thymidine incorporation during the anti-
proliferative response to tRA (Fig. 5 B). After 4 d of 1 mM
tRA treatment, [3H]thymidine incorporation was reduced
by 54% in WT cells relative to vehicle-treated control cells,
and only by 20% in RXRa2/2 and RXRa2/2/RARa2/2
cells. In contrast, there was no inhibition of [3H]thymidine
incorporation in RXRa2/2/RARg2/2 cells.
FACS® analysis has previously shown that tRA treat-
ment of WT F9 cells results in an accumulation of cells in
the G0 and G1 phases of the cell cycle, and that this accu-
mulation was decreased in RXRa2/2 cells (Clifford et al.,
1996) (Fig. 5 C). The cell cycle profile of untreated
RXRa2/2/RARa2/2 and RXRa2/2/RARg2/2 cells was the
same as that of WT and RXRa2/2 cells. After 5 d of 1 mM
tRA treatment, the proportion of cells in the G0 and G1
phases, was 71% for WT cells, whereas it was lower for
RXRa2/2 and RXRa2/2/RARa2/2 cells (38 and 40%, re-
spectively; Fig. 5 C, compare b, d, and f). Interestingly, the
cell cycle profile of RXRa2/2/RARg2/2 cells was not sig-
nificantly affected by tRA treatment, and was almost iden-
tical to that of untreated WT cells (Fig. 5 C, compare h
with g and a).
To further dissect the roles of RARs and RXRs in the
control of proliferation, WT and mutant F9 cells were
treated for 6 d with tRA or receptor-selective retinoids,
and cell numbers were counted (Table II). In WT cells,
100 nM RARg agonist efficiently reduced the prolifera-
tion, and 10 nM of the same agonist, which had no effect
on its own, synergized with 1 mM panRXR agonist. The effect
of these retinoids on proliferation was reduced, while not
abolished, in RXRa2/2 and RXRa2/2/RARa2/2 cells, in-
dicating that RXRa can be partially replaced by RXR(b1g)
for synergizing with RARg (see Table IV). Interestingly,
the RARg/panRXR agonist combination was more effi-
cient in RARa2/2 cells than in WT cells, revealing that
RARa partially hinders the antiproliferative effect of
RARg in WT cells (Table II; see Table IV). As expected,
this combination did not inhibit the proliferation of
RARg2/2 and RXRa2/2/RARg2/2 cells. The combination
of 100 nM RARa and 1 mM panRXR agonists, which re-
duced the proliferation of WT cells less efficiently than the
RARg/panRXR agonist combination, was more efficient
in RARg2/2 cells than in WT cells (Table II), indicating
that RARg partially hinders the antiproliferative effect of
RARa in WT cells (see Table IV). The RARa/panRXR
agonist combination had no effect on the proliferation of
RXRa2/2 cells, showing that RARa can only synergize
with RXRa to inhibit proliferation (see Table IV).
Surprisingly, a treatment with 10 and 100 nM RARa ag-
onist increased the number of RXRa2/2/RARg2/2 cells,
indicating that RARa can mediate a proliferative effect in
the absence of both RXRa and RARg. As expected, the
RARa/panRXR agonist combination did not affect prolif-
eration of RARa2/2 and RXRa2/2/RARa2/2 cells. Neither
the RARb agonist alone nor in combination with the pan-
RXR agonist affected the proliferation of WT, RXRa2/2,
RARa2/2, and RXRa2/2/RARa2/2 cells, whereas this com-
bination synergistically reduced the proliferation of RARg2/2
cells. Note that 500 nM RARb agonist alone increased the
Figure 6. The apoptotic response to tRA is severely impaired in
RXRa2/2 and RXRa2/2/RARa2/2 cells, and is abrogated in
RXRa2/2/RARg2/2 F9 cells. WT (a and b), RXRa2/2 (c and d),
RARa2/2 (e and f), RXRa2/2/RARa2/2 (g and h), RARg2/2 (i
and j), and RXRa2/2/RARg2/2 (k and l) cells were treated for 6 d
with control vehicle (a, c, e, g, i, and k) or 1 mM tRA (b, d, f, h, j,
and l), followed by fixation and staining with Hoechst dye. Cells
were photographed under a fluorescence microscope at 3120
magnification. Arrows indicate condensed chromatin in the nu-
clei of apoptosing cells or in apoptotic bodies. Arrowheads indi-
cate mitotic cells. Bar, 150 mm.Chiba et al. Function of RXR/RAR Heterodimers in F9 Cells 743
cell number of RXRa2/2/RARg2/2 cells, and that this ef-
fect was enhanced by addition of 1 mM panRXR agonist.
Thus, the presence of RARg not only hinders the anti-
proliferative effect of the RXRa/RARb pair, but also the
proliferation-promoting effects of the combinations of
RXR(b1g) with RARb, showing again that knockouts
generate artifactual effects not observed under WT condi-
tions, as already seen above in the case of F9 cell differen-
tiation (see Table IV).
Function of RXRs and RARs for the Retinoid-induced 
Apoptotic Response of F9 Cells
Since retinoids can induce apoptosis, which also contrib-
utes to the decrease in cell number in retinoid-treated F9
cells (Atencia et al., 1994), we determined the extent of
the tRA-induced apoptotic response of WT and mutant F9
cells by FACS® analysis. Sub-2N–size, DNA-containing
particles corresponding to “apoptotic bodies” appeared in
WT cells after 5 d of tRA treatment, whereas they were
not detected in tRA-treated RXRa2/2 (see also Clifford et
al., 1996), RXRa2/2/RARa2/2, and RXRa2/2/RARg2/2
cells (Fig. 5 C, compare d, f, and h with b [arrow]). Apop-
tosis was confirmed by staining with the DNA-binding flu-
orochrome Hoechst 33258. Apoptotic particles and con-
densed chromatin were similarly observed in tRA-treated
WT and RARa2/2 cells (Fig. 6, a, b, e, and f; Table III). In
contrast, tRA-induced apoptosis was reduced in RARg2/2
cells, rarely seen in RXRa2/2 (Clifford et al., 1996) and
RXRa2/2/RARa2/2 cells, and abolished in RXRa2/2/
RARg2/2 cells (Fig. 6, c, d, and g–l; Table III). Note that a
background level of apoptosis occurred at high cell density
even in the absence of tRA, as previously mentioned (Clif-
ford et al., 1996).
To further investigate the role played by the different
RAR and RXR isotypes in apoptosis, WT and mutant F9
cells were treated for 6 d with receptor-selective retinoids,
and stained with Hoechst dye (Table III). In WT cells, 100
nM RARg agonist triggered apoptosis, and the addition of
1 mM panRXR agonist resulted in a synergistic effect. The
effect of these retinoids was markedly reduced in RXRa2/2
and RXRa2/2/RARa2/2 cells, indicating that RXRa can
only poorly be replaced by RXR(b1g) for this response
(Table IV). In contrast, the RARg/panRXR agonist com-
bination was more efficient in RARa2/2 cells than in WT
cells, indicating that RARa partially prevents the apop-
totic response mediated by RARg in WT cells (Table IV).
As expected, this combination had no effect on the apop-
tosis of RARg2/2 and RXRa2/2/RARg2/2 cells. Neither
the RARa/panRXR nor the RARb/panRXR agonist
combination induced the apoptosis of WT, RXRa2/2,
RARa2/2, RXRa2/2/RARa2/2, and RXRa2/2/RARg2/2
cells, whereas they weakly triggered apoptosis of RARg2/2
cells (Table III). 100 nM Am80, which acts as panRAR ag-
onist at this concentration (Hashimoto et al., 1990), was as
efficient as 100 nM RARg agonist for WT, RXRa2/2,
RARa2/2, and RXRa2/2/RARa2/2 cells. The panRAR/
panRXR combination was more effective than either the
RARa/panRXR or the RARb/panRXR combination in
RARg2/2 cells, whereas these retinoids had no effects on
the apoptosis of RXRa2/2/RARg2/2 cells (Table III).
Thus, RARg fully prevents the weak apoptotic response
that can be mediated by the RXRa/RARa and RXRa/
RARb pairs, and mutation of RARg artifactually gener-
ates some functional redundancy (Table IV).
Discussion
In vitro studies using either cell-free systems or cultured
cells cotransfected with vectors overexpressing the various
retinoid receptors and cognate recombinant reporter
genes, have suggested that RXR/RAR heterodimers could
be the functional units transducing the retinoid signal in
vivo. These studies have also indicated that the various
RXR/RAR heterodimers, resulting from the combination
of either one of three RXRs (a, b, or g) with either one of
the three RARs (a, b, or g), could be differentially in-
volved in the numerous physiological events that are con-
trolled by retinoids in vivo (Chambon, 1994, 1996). The re-
sults of RAR and RXR gene knockout studies in the
mouse have supported these suggestions, but their inter-
pretation remains equivocal, in particular because cell-
Table III. Effect of Various Retinoids on Apoptosis of WT and Mutant F9 Cells
WT and mutant F9 cells
Treatment WT RXRa2/2 RARa2/2
RXRa2/2
RARa2/2 RARg2/2
RXRa2/2
RARg2/2
Ethanol (2)( 2 )( 2 )( 2 )( 2 )( 2 )
1 mM tRA 11 6 11 6 1 (2)
1 mM panRXR agonist (2) (2)( 2 )( 2 )( 2 )( 2 )
100 nM RARa agonist (2)( 2 )( 2 )( 2 )( 2 )( 2 )
500 nM RARb agonist (2)( 2 )( 2 )( 2 )( 2 )( 2 )
10 nM RARg agonist (2)N D ( 2 )N DN DN D
100 nM RARg agonist 16 * 16 *( 2 )( 2 )
100 nM panRAR agonist 16 * 16 *6( 2 )
100 nM RARa 1 1 mM panRXR agonists (2)( 2 )( 2 )( 2 )6 ( 2 )
500 nM RARb 1 1 mM panRXR agonists (2)( 2 )( 2 )( 2 )6 ( 2 )
10 nM RARg 1 1 mM panRXR agonists 6 (2) 1 (2)N DN D
100 nM RARg 1 1 mM panRXR agonists 11 6 11 6 (2)( 2 )
100 nM panRAR 1 1 mM panRXR agonists 11 6 11 6 1 (2)
WT and mutant F9 cells were treated for 6 d in monolayer culture with the indicated retinoids, and their apoptosis was scored according to the proportion of apoptotic nuclei and
subcellular fragments upon staining of fixed cells with Hoechst 33258, as shown in Fig. 6. 11, .10% ; 1, 1–10%; 6, ,1%; (2), no visible effect; asterisks, less than that in
combination with 1 mM panRXR agonist; ND, not determined. RARa, RARb, RARg, and panRXR agonists were as in Table 1. The panRAR agonist was AM80.The Journal of Cell Biology, Volume 139, 1997 744
autonomous and non–cell-autonomous effects cannot be
distinguished in the intact animal (Kastner et al., 1995,
1997).
The aim of the present study was to determine the ac-
tual role of the various RXR/RAR combinations as retin-
oid transducers in a well-established, cell-autonomous sys-
tem, namely that provided by the retinoid-responsive F9
EC cells. To this end, differentiation into primitive, pari-
etal, and visceral endoderms, as well as antiproliferative
and apoptotic responses have been studied in RXR and
RAR single or compound mutant F9 EC cells cultured in
the presence of either tRA or panRXR- and/or RAR iso-
type-selective synthetic retinoids. Our present results are
summarized in Table IV with relevant data from previous
reports (Roy et al., 1995; Clifford et al., 1996; Taneja et al.,
1996), and lead to several important conclusions, which
Table IV. Summary of the Involvement of the Various RARs and RXRs in the Transduction of the Retinoid Signal in F9 Cells, as 
Deduced from the Present and Previous Studies of RAR and RXR Mutant Cells and the Use of Receptor-specific Retinoids
Retinoid-induced events and RXR/RAR
pairs capable of transducing the signal Role of RXRs Role of RARs
Primitive endodermal differentiation RARg
RARg ligand active on its own at saturating
RXR ligand inactive on its own (Roy et al., 1995) concentration (Taneja et al., 1996)
RARg2/2 cells differentiate very poorly
(Boylan et al., 1993)
RXRa/RARg in all instances RXRa2/2 cells differentiate very poorly
(Clifford et al., 1996)
synergizes with RXRa at suboptimal ligand
concentration (Clifford et al., 1996)
weakly hindered by RARa in WT cells
(Taneja et al., 1996)
RXR ligand is required at suboptimal concentration RARa
of RARg ligand (Roy et al., 1995; Taneja et al., 1996) RARa ligand inactive on its own (Taneja et al., 1996)
RARa2/2 cells differentiate normally
(Boylan et al., 1995)
can poorly replace RARg provided RXRa is activated
RXRa can be poorly replaced by RXR(b1g) RARb
provided that RARg is present inactive or very poorly active (Taneja et al., 1996)
Visceral endodermal differentiation RARg
RXR ligand inactive on its own
RXR ligand is required at suboptimal concentration
of a RAR ligand
RXRa can be efficiently replaced by RXR(b1g)
provided that RARg is present
RXRa prevents efficient synergism between
RXR(b 1 g) and RARg
indispensable in WT cells
RARg ligand active on its own at saturating
concentration
RXRa/RARg in WT cells synergizes with RXRs at suboptimal ligand
concentration
hindered by RARa in WT cells
RARa
RXR(b1g)/RARg in absence RARa ligand inactive on its own or very poorly active
of RXRa (efficiently) RARa2/2 cells differentiate normally
synergizes with RXRa in the absence of RARg
RXRa/RARa or RARb in hindered by RARg in WT cells
absence of RARg (efficiently) RARb
RARb ligand inactive on its own or very poorly active
synergizes with RXRa in the absence of RARg
blocked by RARg in WT cells
Inhibition of proliferation RARg
not indispensable in WT cells
RXRa/RARg or RARa in WT cells RARg ligand active on its own at saturating
concentration
RXR ligand inactive on its own synergizes with RXRs at suboptimal ligand
concentration
partially hindered by RARa in WT cells
RXRa/RARb in absence of RARg RXR ligand is required at limiting concentration
of RAR ligand
RARa
RARa ligand inactive on its own
synergizes with RXRa in WT cells
RXR(b1g)/RARg in absence
of RXRa
RXRa can be partially replaced by RXR(b1g)
provided that RARg is present
partially hindered by RARg in WT cells
RARb
RARb ligand inactive on its own
synergizes with RXRa in the absence of RARg
blocked by RARg in WT cells
Induction of proliferation in RARa
RXRa2/2/RARg2/2cells RARa ligand active on its own
RXR ligand inactive on its own RARb
RXR(b1g)/RARa RARb ligand active on its own
RXR(b1g)/RARb synergizes with RXR(b1g)Chiba et al. Function of RXR/RAR Heterodimers in F9 Cells 745
are in keeping with those recently drawn from a study of
the expression of RA-responsive genes in the same mutant
F9 EC cells (Chiba et al., 1997).
Taken together, our genetic data and those obtained
with selective retinoids in WT or mutated cells establish
that RXR/RAR pairs are always involved in the transduc-
tion of the retinoid signal, irrespective of the nature of the
retinoid-induced event examined (differentiation, antipro-
liferative, or apoptotic effects). This is obvious from both
the comparison of single and double mutants, and the
combined use of the panRXR ligand with suboptimal con-
centrations of either one of the RAR isotype–specific, syn-
thetic retinoids. Thus, since the panRXR-specific agonist
is never active on its own, all cellular events induced by re-
tinoids in F9 EC cells appear to be mediated by RXR/
RAR heterodimers. Note that the “subordination” of
RXRs to RARs (i.e., that a RXR cannot be transcription-
ally activated unless its heterodimer RAR partner is
liganded), which has been repeatedly observed in different
cell systems (Roy et al., 1995; Chen et al., 1996; Horn et al.,
1996; Taneja et al., 1996), as well as in some in vitro studies
(Durand et al., 1994; Apfel et al., 1995; Forman et al.,
1995), may be important to prevent the promiscuous acti-
vation of the retinoid and other signaling pathways (e.g.,
those of thyroid hormones and vitamin D3) by RXR
ligands (Mangelsdorf and Evans, 1995; Chambon, 1996).
The dispensability of the RXR ligand that can be observed
in some instances when a saturating amount of a RAR-
selective ligand (notably in the case of RARg) is used, has
been previously noted (Roy et al., 1995). This dispensabil-
ity most probably reflects the fact that the RAR activation
functions of RXR/RAR heterodimers alone are sufficient
to trigger the expression of the genes involved in the cellu-
lar event considered, whereas the synergistic effect of the
activation functions of the RXR heterodimeric partner be-
comes indispensable at lower concentrations of the RAR
ligand (Clifford, J., unpublished results), which are proba-
bly closer to physiological retinoic acid concentrations.
The second important conclusion of the present study is
that the various RXR/RAR heterodimers that can be
formed in F9 EC cells exhibit some functional specificity.
Indeed, each of the cellular events that are RA-induced in
F9 cells appears to preferentially involve a specific RXR/
RAR isotype combination (or set of combinations) (Table
IV). It appears that in all cases the RA signal is transduced
by RXRa/RARg heterodimers in WT F9 cells. However,
both the RXRa/RARg and RXRa/RARa heterodimers
can mediate the RA-induced inhibition of WT F9 cell pro-
liferation. Thus, in WT F9 cells, depending on the cellular
event considered, different RXR/RAR isotype heterodimers
possess both specific functions and redundant functions
shared with other heterodimers. Interestingly, additional
redundant functions, not seen in WT cells, are revealed
when either RXRa or RARg are not expressed. The pres-
ence of RARg often hinders or blocks the activity of RARa
and RARb, where the presence of RXRa can hinder the
activity of RXR(b1g) (Table IV). In several instances, the
retinoid-induced cellular events mediated by RXRa/RARg
in WT cells can be mediated by RXR(b1g)/RARg hetero-
dimers in the absence of RXRa, and by RXRa/RAR(a
and/or b) heterodimers in the absence of RARg (Table
IV). Again, these redundancies vary according to the cel-
lular event examined, further supporting the conclusion
that the different RXR/RAR isotype heterodimers possess
some functional specificity.
The third conclusion is that gene knockouts generate ar-
tifactual conditions unmasking potential functional redun-
dancies, which actually do not occur in the WT situation
(Table IV). For instance, in the case of visceral endoderm
differentiation, RXR(b1g)/RARg heterodimers can effi-
ciently substitute for RXRa/RARg heterodimers in the
absence of RXRa; in addition, either RXRa/RARa or
RXRa/RARb heterodimers can efficiently substitute for
RXRa/RARg heterodimers in the absence of RARg, even
though RXRa/RARg heterodimers essentially mediate
this differentiation in WT F9 EC cells. How the presence
of RXRa/RARg heterodimers prevents potentially func-
tionally redundant heterodimers from transducing the RA
signal is unknown, but it could be related to their differen-
tial affinities for the RAREs of the target genes involved
in the cellular processes induced by RA in F9 cells. In any
event, it is clear that the functional redundancies that are
revealed by gene knockout cannot be taken as evidence
for a lack of functional specificity of the knockout gene
product under WT physiological conditions. It is not un-
likely that many of the functional redundancies that have
Table IV. (continued)
Retinoid-induced events and RXR/RAR pairs 
capable of transducing the signal Role of RXRs Role of RARs
Apoptosis RARg
indispensable in WT cells
RXRa/RARg in WT cells RXR ligand inactive on its own RARa ligand active on its own at saturating ligand
concentration
RXR(b1g)/RARg in absence of
RXRa, but very inefficiently
RXRa ligand is required at suboptimal ligand
concentration of RAR ligand
synergizes with RXRa at suboptimal ligand
concentration
hindered by RARa in WT cells
RARa
RXRa/RARa or RARb in absence of 
RARg, but inefficiently
RXRa can be poorly replaced by RXR(b1g) 
provided that RARg is present
RARa ligand inactive on its own
weakly synergizes with RXRa in the absence of RARg
blocked by RARg in WT cells
RARb
RARb ligand inactive on its own
weakly synergizes with RXRa in the absence of RARg
blocked by RARg in WT cellsThe Journal of Cell Biology, Volume 139, 1997 746
been so far revealed by mouse gene knockouts are simi-
larly artifactually generated.
Interestingly, our present study also reveals that differ-
ent RXR/RAR heterodimers can have opposite effects on
cell proliferation of F9 cells. RXRa/RARg or RARa het-
erodimers are involved in the transduction of the antipro-
liferative effect of RA, but in the absence of RXRa and
RARg, both RXR(b1g)/RARa and RARb heterodimers
can mediate a proliferative effect of RA (Tables II and
IV). Note that induction of proliferation of certain cell
types by retinoids has been previously reported (Amos
and Lotan, 1990; Koshimizu et al., 1995). Our present ob-
servations on retinoid-induced cell antiproliferative and
proliferative effects, strengthen the conclusion that differ-
ent RXR/RAR heterodimers can exert specific functions.
These observations also suggest that the actual set of retin-
oid receptors present in a given cell may have a profound
influence on the effects generated by a retinoid treatment.
It is interesting to note that morphological differentia-
tion of WT F9 EC cells can be efficiently triggered by a
combination of panRXR/RARg-specific (BMS961) ago-
nists, but not by a combination of panRXR/RARa-spe-
cific (BMS753) agonists, nor by a combination of a pan-
RXR/RARb-specific (BMS453) agonists. In contrast, P19
EC cell differentiation can be triggered by either a pan-
RXR/RARg or a panRXR/RARa agonist combination,
but not by a panRXR/RARb agonist combination (Taneja
et al., 1996), whereas the differentiation of the NB4 acute
promyelocytic leukemia cells, and HL60 myeloblastic leu-
kemia cells can be triggered by a combination of a pan-
RXR/RARa or a panRXR/RARb agonists, but not by a
panRXR/RARg agonist combination (Chen et al., 1996).
Similarly, the apoptosis of NB4 cells can be induced by a
panRXR/RARb agonist combination (Chen et al., 1996),
which on the other hand is inefficient in the case of F9 cells
(Table III). Thus, different RAR isotype-specific agonists
acting synergistically with a panRXR agonist are not only
more restricted than tRA in their effects on various cellu-
lar events in a given cell type (e.g., differentiation and apop-
tosis), but also affect differentially these events in a cell-
specific manner. These cell type–specific effects of synthetic
retinoids may extend their potential for therapeutical use.
Finally, to our best knowledge, this study is the first re-
port of multiple gene targeting (two alleles of two genes)
in a mammalian cell–autonomous system. Similar ap-
proaches will allow the inactivation of any set of genes in a
given cell, which will undoubtedly and particularly useful
to elucidate the molecular mechanisms underlying com-
plex biological events.
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